AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9951432
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 7.5 mg hydrocodone bitartrate with 200 mg ibuprofen
Trial: 7790461
Drug: bismuth-antibiotic
RxNorm normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bismuth-antibiotic
Trial: 30607985
Drug: Vestibular rehabilitation
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vestibular rehabilitation therapy (VRT) plus placebo
Trial: 15086356
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid plus vitamin B(6) (5 mg of folic acid plus 250 mg of vitamin B(6) daily)
Trial: 8389710
Drug: T3 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 therapy
Trial: 3318711
Drug: Penicillamine 20
RxNorm normalized name: Penicillamine
DrugBank: Penicillamine (DB00859)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillamine 20 mg/kg/day
Trial: 16357522
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine (single or double dose, weekly for four weeks and monthly thereafter)
Trial: 16357522
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine (double dose)
Trial: 16357522
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine (good antibody response)
Trial: 16357522
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine (serum EGF decreased below 168 pg/ml)
Trial: 16357522
Drug: EGF vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF vaccine (overall treatment)
Trial: 15273838
Drug: Dexamethasone administered
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administered before antibiotic therapy (Group I - 25 patients)
Trial: 15273838
Drug: Dexamethasone administered
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administered concomitantly with antibiotics (Group II - 19 patients)
Trial: 15273838
Drug: Dexamethasone administered
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administered after beginning antibiotic therapy (Group III - 14 patients)
Trial: 809253
Drug: Intravenous TRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous TRH
Trial: 8510087
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg and Hydrochlorothiazide 25 mg daily for 16 weeks
Trial: 8510087
Drug: Captopril or
RxNorm normalized name: captopril Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril or Hydrochlorothiazide monotherapy for 4 weeks
Trial: 2879981
Drug: Edmonston-Zagreb strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb strain by subcutaneous injection
Trial: 2879981
Drug: Schwarz strain
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz strain by subcutaneous injection
Trial: 31302339
Drug: SPX-101 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPX-101 (20 to 240 mg single doses and 10 to 120 mg BID for 14 days)
Trial: 31302339
Drug: SPX-101 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPX-101 (10 mg-120 mg BID for 7 days)
Trial: 26988864
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + 1.2% ATV gel
Trial: 25610954
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL of chocolate milk daily
Trial: 19843656
Drug: Asenapine 5
RxNorm normalized name: asenapine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 5 mg BID for 10 days followed by 10 mg BID for 6 days
Trial: 19843656
Drug: Asenapine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine 15 mg BID for 10 days followed by 20 mg BID for 6 days
Trial: 19843656
Drug: Quetiapine 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 375 mg BID for 16 days
Trial: 17074351
Drug: Oral estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estrogen supplementation
Trial: 14764210
Drug: Isobaric rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric rectal distension
Trial: 8737557
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy with topical beta blockers
Trial: 3595257
Drug: Mitoxantrone (M)
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (M) mixed with poly(I).poly(C) (90 mg/m2)
Trial: 3595257
Drug: Free Mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free Mitoxantrone (M) (30 mg/m2)
Trial: 22717330
Drug: rHA 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA 45 μg with Advax™ adjuvant
Trial: 22717330
Drug: rHA 3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHA 3, 11 or 45 μg with or without adjuvant
Trial: 18795960
Drug: TMC125 (etravirine)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TMC125 (etravirine) 800 mg bid
Trial: 15657693
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids (prednisolone acetate 1% eye drops 5x/day for 6 months)
Trial: 15657693
Drug: Combined systemic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined systemic (fluocortolone 1 mg/kg body weight per day tapered within 3 weeks) and topical steroids
Trial: 12629101
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg T enanthate, im, weekly plus 125 micro g LNG, orally, daily (T+LNG)
Trial: 12629101
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of T+LNG
Trial: 11279969
Drug: Intranasal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal lidocaine 4%
Trial: 11279969
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo 0.5 mL
Trial: 1907362
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate (0.12 mg/kg)
Trial: 1907362
Drug: Morphine-6-glucuronide (M6G:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-glucuronide (M6G: 0.03 mg/kg)
Trial: 1907362
Drug: Morphine-6-glucuronide (M6G:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-6-glucuronide (M6G: 0.06 mg/kg)
Trial: 6351658
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (prednisone, vincristine, and L-asparaginase)
Trial: 24485633
Drug: High-dose furosemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose furosemide (HDF, n=50, 20mg/h)
Trial: 24485633
Drug: Low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide and low-dose dopamine (LDFD, n=56, 5mg/h and 5 μg kg(‐1)min(‐1))
Trial: 24485633
Drug: Low-dose furosemide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose furosemide (LDF, n=55, 5mg/h)
Trial: 18034900
Drug: Order of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Order of administration (telephone interview first)
Trial: 16136843
Drug: Caregiver training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver training program (N = 24) consisting of four sessions, including watching investigators administer the Texas Functional Living Scale and cueing patients to perform tasks.
Trial: 12586806
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atrasentan
Trial: 7728983
Drug: 300 g
RxNorm normalized name: Zantac 300 GELdose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g of cooked Brussels sprouts per day
Trial: 27932571
Drug: Esmolol, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol, 1 mg/kg before aortic cross‐clamping and 2 mg/kg with Custodiol® crystalloid cardioplegia
Trial: 22952293
Drug: Intravesical bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical bacillus Calmette‐Guérin therapy
Trial: 8895262
Drug: Dexamethasone 150
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone 150 micrograms/kg up to a maximum dose of 8 mg, administered IV before surgery
Trial: 6395464
Drug: Piperacillin 150
RxNorm normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperacillin 150 mg/kg/day for 7.2 ± 2.75 days
Trial: 6395464
Drug: Carbenicillin 200
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin 200 mg/kg/day for 7.5 ± 2.90 days
Trial: 15864235
Drug: ezetimibe/simvastatin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin and atorvastatin
Trial: 16540080
Drug: Individual cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive behaviour therapy (CBT) for 10 weeks
Trial: 16540080
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behaviour therapy (CBT) for 10 weeks
Trial: 12010934
Drug: Antiarrhythmic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agents (Class IA)
Trial: 12010934
Drug: Antiarrhythmic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agents (Class IC)
Trial: 12010934
Drug: Antiarrhythmic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic agents (Class III)
Trial: 12010934
Drug: All drug
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All drug classes
Trial: 7641048
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium hyaluronate
Trial: 30608463
Drug: TDP patch
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDP patch
Trial: 30608463
Drug: Lubricant gel
RxNorm normalized name: Surgilube Lubricant Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lubricant gel patch (control)
Trial: 26165012
Drug: Mild OSAHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild OSAHS Montelukast Treatment (MM) group - treated with leukotriene receptor antagonists (LTRAs)
Trial: 26165012
Drug: Mild OSAHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild OSAHS Adenotonsillectomy Treatment (MAT) group - treated with adenotonsillectomy
Trial: 26165012
Drug: Mild OSAHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild OSAHS Montelukast Treatment (MM) group
Trial: 26165012
Drug: Severe OSAHS
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe OSAHS Montelukast Treatment (SM) group - treated with LTRAs
Trial: 26165012
Drug: Severe OSAHS
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe OSAHS Adenotonsillectomy Treatment (SAT) group - treated with adenotonsillectomy
Trial: 26165012
Drug: Mild OSAHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild OSAHS Adenotonsillectomy Treatment (MAT) group
Trial: 26165012
Drug: Severe OSAHS
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe OSAHS Adenotonsillectomy Treatment (SAT) group
Trial: 26165012
Drug: Severe OSAHS
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe OSAHS Montelukast Treatment (SM) group
Trial: 12652333
Drug: Bilateral subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with technetium‐99m
Trial: 12652333
Drug: Bilateral subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral subcutaneous hand injection of polyclonal human immunoglobulin G (HIgG) labelled with indium‐111
Trial: 9352953
Drug: Doxorubicin combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin combination
Trial: 7506170
Drug: nimesulide (100mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (100mg twice daily)
Trial: 7506171
Drug: diclofenac (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diclofenac (50 mg/kg twice daily)
Trial: 3548627
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2.4 g as a single intravenous dose)
Trial: 27311846
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg flurbiprofen
Trial: 18803888
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg diclofenac sodium
Trial: 20467920
Drug: high-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose dexamethasone plus thalidomide
Trial: 20467920
Drug: high-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose dexamethasone plus lenalidomide (RD)
Trial: 20467920
Drug: high-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high-dose dexamethasone plus bortezomib (VD)
Trial: 7328226
Drug: Experimental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatment group
Trial: 26988766
Drug: Blood insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood insulin levels at the start of EXER compared with CON and FAST
Trial: 20345390
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (target hemoglobin 9.5-11.0 g/dL and 11.5-13.0 g/dL)
Trial: 17030095
Drug: Pain-reducing ointment
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-reducing ointment (placebo)
Trial: 17030095
Drug: Neutral ointment
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral ointment (control)
Trial: 15204314
Drug: Combination low-fat/low-energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination low-fat/low-energy diet
Trial: 10404809
Drug: Intranasal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2 (300 microg/day)
Trial: 10404809
Drug: Intranasal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2 (100, 200, 300, and 400 microg/day)
Trial: 10404809
Drug: Oral E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2 (1 and 2 mg/day)
Trial: 2404636
Drug: Nicardipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (30 mg t.i.d.)
Trial: 2404636
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg b.i.d.)
Trial: 7043751
Drug: Sulfadoxine 20
RxNorm normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 1)
Trial: 7043751
Drug: Sulfadoxine 30
RxNorm normalized name: Sulfadoxine
DrugBank: Sulfadoxine (DB01299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfadoxine 30 mg/kg and pyrimethamine 1.5 mg/kg (Group 2)
Trial: 7043751
Drug: Quinine 10
RxNorm normalized name: quinine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine 10 mg/kg 8 hourly for 5 days plus sulfadoxine 20 mg/kg and pyrimethamine 1.0 mg/kg (Group 3)
Trial: 24321091
Drug: HIV‐1 DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV‐1 DNA vaccine at months 0, 1 and 3; HIV‐1 MVA vaccine at months 9 and 21
Trial: 20638452
Drug: Intranasal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal vaccine
Trial: 20638452
Drug: Injectable vaccine
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable vaccine
Trial: 20638452
Drug: Study interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study interventions (enhanced advertising, choice of vaccine type, and incentive)
Trial: 20638452
Drug: Intentional vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intentional vaccine choice
Trial: 10617952
Drug: High iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High iron bioavailability diet (14.4 mg nonheme Fe/d, 1.8 mg heme Fe/d)
Trial: 10617952
Drug: Low iron
RxNorm normalized name: Slow Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low iron bioavailability diet (15.3 mg nonheme Fe/d, 0.1 mg heme Fe/d)
Trial: 10617952
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of high and low bioavailability diets
Trial: 10617952
Drug: Low bioavailability
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low bioavailability diet
Trial: 8654899
Drug: Nucleus cochlear
RxNorm normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleus cochlear implant users
Trial: 3859954
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg PGE2 gel applied endocervically
Trial: 3859954
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg PGE2 gel applied endocervically
Trial: 3859954
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg PGE2 given pericervically through a portio adapter
Trial: 18787893
Drug: Naproxen 250
RxNorm normalized name: naproxen 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 250 mg BD
Trial: 12848634
Drug: Valdecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (40 mg b.d.)
Trial: 1992102
Drug: Dapsone 200
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone 200 mg daily
Trial: 6744646
Drug: Noradrenaline (alpha‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenaline (alpha‐1 adrenoceptor agonist)
Trial: 6744646
Drug: Salbutamol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (beta 2‐adrenoceptor agonist)
Trial: 30212253
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein diet (1.1 g·kg‐1·day‐1, 39% fat)
Trial: 30212253
Drug: Higher protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher protein diet (2.1 g·kg‐1·day‐1, 23% fat)
Trial: 24906174
Drug: Lercanidipine 20
RxNorm normalized name: lercanidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 20 mg + Enalapril 20 mg
Trial: 24906174
Drug: Lercanidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine (10 or 20 mg) or Enalapril (10 or 20 mg)
Trial: 21293245
Drug: Stereotactic radiosurgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stereotactic radiosurgery (SRS) and whole brain radiation therapy
Trial: 20559273
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy (treatment of glycemia, vasoactive drugs)
Trial: 22281182
Drug: Miglustat 200
RxNorm normalized name: Miglustat
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Miglustat 200 mg t.i.d. for 8 days
Trial: 16339692
Drug: Serum non-transferrin-bound
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum non-transferrin-bound iron (NTBI) levels measured weekly during transfusion cycles
Trial: 8683231
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (CPT-11) at a dose of 145 mg/m2 administered as a 90-minute infusion with G-CSF and antidiarrheal support